Osage Partners related stories
All articles and analysis
VCs on the moveScott Bonham named co-chair of C100, while Heidi Roizen named operating partner
VC-backed AGTC debuts IPOFlorida-based biotech company Applied Genetic Technologies Corp. has launched its IPO after pricing its offering of over 4.16 million shares at $12 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol "AGTC." BMO Capital Markets and Wedbush PacGrow Life Sciences are the lead underwriters. Its backers include InterWest Partners, Skyline Ventures, Intersouth Partners, MedImmune Ventures, Osage University Partners, SR One and Alta Partners.
- Kolltan Pharmaceuticals rakes in $60 mln
Kolltan Pharmaceuticals said Wednesday that it has secured $60 million in Series D financing. The investors included KLP Enterprises, Deerfield Management, HBM Healthcare Investments Ltd., Purdue Pharma and Osage University Partners. Based in New Haven, Conn., Kolltan Pharmaceuticals is a biopharmaceutical company that targets receptor tyrosine kinases.
- Osage Venture Partners promotes Drahms and hires Phelan as a venture partner
Osage Venture Partners has promoted David Drahms to principal and hired Michael Phelan as a venture partner. Drahms joined Osage Venture Partners in 2005 while Phelan was previously CEO of SevOne.
- VC-backed Atterocor expands clinical advisory board
Atterocor said Wednesday that it has beefed up its clinical advisory board with eight additions. Among them are Dr. Wiebke Arlt and Dr. Eric Baudin. Based in Ann Arbor, Michigan, Atterocor is a company that is focused on treating adrenal cancer. Its backers include Frazier Healthcare, Osage University Partners and 5AM Ventures.
- Infinio nets $12 mln in Series B funds
Infinio said Monday that it has closed $12 million in Series B financing. Investors included Bessemer Venture Partners, Highland Capital Partners, Lightspeed Venture Partners and Osage University Partners. Based in Cambridge, Mass., Infinio is a provider of data storage performance solutions.
- Immune Design closes $49 mln Series C funding round
Immune Design, a biotechnology company, has closed a $49 million Series C funding round, which includes an upfront investment of $32.5 million and the right of the investor syndicate to inject another $16.5 million as the program progresses. Financing was led by The Column Group, new investor Topspin Partners and existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investments. In addition, Sanofi-Genzyme BioVentures joined as a new investor.
- Sideris Pharmaceuticals racks up $32 mln, also could be acquired by Novartis for up to $300 mln
Sideris Pharmaceuticals said Tuesday that it has closed $32 million in Series A financing. MPM Capital led the round with participation from Hatteras Venture Partners and Osage University Partners. In addition to the financing, Sideris has inked an agreement with Novartis Pharmaceuticals that grants Novartis the exclusive right to acquire Sideris in a transaction that could reach up to $300 million. Also, Sideris has named Dr. Ansbert Gadicke and Dr. Kazumi Shiosaki, managing directors of MPM Capital and Dr. Doug Reed, general partner of Hatteras Venture Partners, to the Sideris board of directors. Sideris Pharmaceuticals is a biopharmaceutical company that develops treatments for transfusion-related iron overload.
- OrbiMed Advisors Leads $45.9 Mln Series C Round for Otonomy
Otonomy said Wednesday that it has raised $45.9 million in Series C financing. The lead investor was OrbiMed Advisors. New investors Aperture Venture Partners and Osage University Partners also participated in the round as did existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech. In conjunction with the financing, OrbiMed's Chau Q. Khuong joins Otonomy's board of directors. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.
- VC-Backed RackWare Names New Board Member
RackWare said Tuesday that it has named Steve Daly to its board of directors. Daly is currently president and CEO of LANDesk. Based in Santa Clara, Calif., and Wayne, Penn., RackWare, which is backed by Kickstart Seed Fund and Osage Venture Partners, is a provider of cloud solutions.